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Uterine sarcomas are uncommon, comprising less than 1% of all
gynecologic neoplasms and 3–7% of all uterine neoplasms. Clinical
manifestations of uterine sarcoma typically consist of vaginal bleeding,
pelvic pain or pressure and an enlarged uterus (D'Angelo and Prat,
2010). Uterine sarcomas can be classiﬁed as either homologous
(consisting of components native to the uterus) or as heterologous
(consisting of components foreign to the uterus such as cartilage and
bone). The majority of uterine sarcomas are homologous (DiSaia and
Creasman, 2012). Heterologous uterine osteosarcomas are distinctly
rare with published references limited to case reports. To our knowl-
edge, 18 cases of primary osteosarcoma arising from the uterus have
been published. We present the ﬁrst case of a 47 year old Asian female
with primary uterine osteosarcoma that exhibited cardiac and pulmo-
nary metastases.
Case
A 47 year old Asian female presented with a six month history of
menometrorrhagia, abdominal pain and early satiety. She also reported
a two month history of chronic cough. Six months prior to symptom
onset, she was in good health. Magnetic resonance imaging of the abdo-
men and pelvis performedﬁvemonths prior to initial ofﬁce presentation
showed a uterus measuring 12 × 9 × 9 cm with a heterogeneously⁎ Corresponding author at: Staten Island University Hospital, Dept of OB/GYN, 475
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7 cm. The ovaries appeared unremarkable. Endometrial biopsy per-
formed threemonths prior to initial ofﬁce presentation showed secreto-
ry endometrium. Pelvic ultrasound performed on the day of initial ofﬁce
presentation showed a uterusmeasuring 17× 14 × 12 cmwithmultiple
intramural leiomyomas andﬁndings suggestive of adenomyosis. The pa-
tient was counseled on treatment options and elected for surgical man-
agement. Given the history of cough, the patient underwent a chest X-
ray pre-operatively and was noted to have multiple scattered pulmo-
nary nodules which were conﬁrmed after CT of the chest with contrast
was performed. CT of the abdomen and pelvis indicated no othermetas-
tases. Given the patient's worsening symptoms, it was decided to pro-
ceed with primary surgical management for pathological conﬁrmation
of malignancy and palliation of symptoms. Total abdominal hysterecto-
my and bilateral salpingo-oophorectomy (TAH/BSO) was performed.
The surgical specimen weighed 1827 g. The uterine corpus mea-
sured 17 × 16 × 16 cm. Approximately 90% of the uterus was displaced
by a soft, friable necrotic tumor that was interspersed with viable tissue
suggestive of smooth muscle and measuring 14 × 11 × 9 cm (Fig. 1).
There was a rim of myometrium surrounding the tumor that measured
1.5 cm. The ovaries and fallopian tubes showed no pathological change.
Calciﬁcations were not grossly evident.
Initial pathologic diagnosis was leiomyosarcoma. However, on
repeat pathologic evaluation, a diagnosis of primary uterine osteosarco-
ma based on the presence of multinucleated giant cells (Fig. 2a) and
osteoid formation with ossiﬁcation (Fig. 2b) was favored. It is possible
that the tumor arose in the setting of a uterine leiomyosarcoma that
underwent heterologous differentiation but there was no evidence of
leiomyosarcoma seen in the pathology specimen. Initial staining
showed that the tumor was positive for caldesmon with focal positivity
to desmin and CD10 while it was negative for cam5.2, pax8, SMA, actin,
CD34, CD117, ER and CA 125. Keratin staining did not support a diagno-
sis of carcinosarcoma. Neither cartilage formation nor carcinomatous el-
ements were present.
On postoperative day 16, the patient presented with dyspnea to the
ofﬁce. CT of the chest showed two intracardiac masses which were ulti-
mately felt to represent tumor; thesemasseswere not present on the CT
of the chest that was performed one month prior. It was elected to not
proceed with cardiac surgery so as to not delay initiation of systemic
chemotherapy. Given the osteosarcoma histology, chemotherapy in
the form of doxorubicin and ifosfamide with mesna was initiated. The
patient experienced a dramatic improvement in her symptoms withinthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Entire gross specimen bivalved.
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doxorubicin and ifosfamide with mesna, CT of the chest, abdomen and
pelvis showed an interval improvement in the size of the pulmonary
metastases.
Imaging performed one month later however indicated an increase
in the size of the pulmonary metastases. There was no change in the
size of the intracardiac masses. She subsequently received one dose of
gemcitabine and decided to enter hospice care. She died six months
after surgery secondary to worsening symptoms associated with the
pulmonary metastases.Fig. 2. a. Osteoclast-like giant cells and pleomorphic tumor cells are distributed within
prominent eosinophilic matrix (osteoid). b. The osteoid is focally calciﬁed, imparting the
appearance of bone.Discussion
Uterine leiomyosarcomas are very aggressive tumors and portend a
poor prognosis. Making a diagnosis preoperatively based on endometri-
al biopsy is difﬁcult as the tumor arises within the smooth muscle.
Leiomyosarcomas have been reported to occur twice as often in
African-American as in Caucasian women. Mean age at diagnosis is
60 years old (DiSaia and Creasman, 2012). Heterologous uterine
osteosarcomas are unusually rarewith instances limited to case reports.
The histologic origin of uterine osteosarcomas may be secondary to
either mesenchymal differentiation or a smooth muscle neoplasm
withmalignant osseousmetaplasia. However, these theories are contro-
versial (Kostopoulou et al., 2002). The ideal chemotherapy regimen for
patients with primary uterine osteosarcoma is unknown given the
rarity of these tumors. Therefore, chemotherapy recommendations are
extrapolated from clinical trials of chemotherapy for uterine sarcomas
and extraskeletal osteosarcomas. In uterine leiomyosarcoma, the com-
bination of doxorubicin and ifosfamide is associated with reported re-
sponse rates of 30–48% and that of gemcitabine and docetaxel with
response rates of 27–40% (Hensley, 2010).
Based on a PubMed Search using the search words “uterus” and
“osteosarcoma,”we found that the age range at timeof diagnosis ranged
from 41 to 82. Grossly, the size range of the tumors ranged from 4 to
40 cm. Of the eleven patients with metastatic uterine osteosarcoma,
ﬁve had abdominal spread and one had metastasis to the skull. Five
patients had pulmonary metastasis. Table 1 summarizes the ﬁndings
associatedwith those previously reported patientswith pulmonaryme-
tastasis and the ﬁndings associated with our case (Stier and Lyman,
1936; Carleton and Williamson, 1961; Jotkowitz and Valentine, 1985;
Emoto et al., 1994; Piscioli et al., 1985; Su et al., 2002). None of the
patients initially presented with pulmonary metastases at the time of
diagnosis. None of the patients had cardiac metastasis.
In our case, the possibility of metastasis from a skeletal osteosarco-
mawas excluded based on the patient's history, physical exam and pre-
operative imaging. Additionally, skeletal osteosarcomas primarily occur
in the ﬁrst two decades of life. Although the distinction between
leiomyosarcoma with heterologous (osseous) elements and “osteosar-
coma” has not been codiﬁed in the gynecologic pathology literature,
the histologic features of the specimen in our case were distinctive
enough to favor the diagnosis of osteosarcoma over leiomyosarcoma.
The histologic ﬁndings were in accordance with the following three
guidelines espoused by Piscioli et al. (1985): primary origin in bone
was excluded, neoplastic osteoid was present, and an epithelial compo-
nent and other speciﬁc homologous or heterologous elements were ab-
sent after conﬁrming the presence of an adequate tissue sampling.
Furthermore, desmin testing was positive which is consistent with
myoblastic differentiation, a ﬁnding associated with osteosarcomas
arising from soft tissue. Although desmin testing aided in supporting
the diagnosis of osteosarcoma, the diagnosis of osteosarcoma is based
on histology, not immunophenotype. Thus, immunohistochemical
results were not used as primary diagnostic indices. The main tumor
entity in our differential diagnosis was malignant mixed mullerian
tumor (MMMT). This was ruled out based on negative keratin staining.
Moreover, the tumor in our case was not described as polypoid and
projecting into the uterine cavity as is the description associated with
MMMT (Su et al., 2002).
This is the ﬁrst case describing a female with primary uterine
osteosarcoma that exhibited cardiac and pulmonary metastases. This
patient's course indicates that although extremely rare, uterine
osteosarcomas, like leiomyosarcomas, do respond to doxorubicin and
ifosfamide. However, this patient's course serves to emphasize the
aggressive nature andmetastatic potential associatedwith uterine oste-
osarcoma given the location of the metastases and progression of the
disease in spite of instituting a comprehensive regimen consisting of
surgery and chemotherapy. The small number of published cases of
uterine osteosarcoma does not allow for clear guidelines on the best
Table 1
Summary of ﬁndings associated with previously reported cases of primary uterine osteosarcoma with pulmonary metastasis and with the present case of osteosarcoma of the uterus.
Source Age Symptoms Size of tumor (if noted), site of metastasis at initial
presentation (if any)
Treatment Clinical duration
Stier and Lyman (1936) 53 Abdominal pain 6 cm, omentum SCH, BSO 2 months
Carleton and Williamson (1961) 82 Vaginal bleeding Bladder; tumor ﬁlled pelvis Intracavity radium 8 months
Jotkowitz and Valentine (1985) 51 Backache, abdominal pain, weight loss Pelvis, omentum, peritoneum None 20 days
Piscioli et al. (1985) 56 Vaginal bleeding 12 cm TAH, BSO, CHT, RT 37 months
Emoto et al. (1994) 67 Abdominal pain 16 cm TAH, BSO 4 months
Su et al. (2002) 62 Abdominal pain 15 cm Biopsy of mass 4 months
Present case 47 Abdominal pain, vaginal bleeding,
early satiety, chronic cough
14 cm, lungs TAH, BSO, CHT 6 months
Abbreviations: SCH: supracervical hysterectomy, TAH: total abdominal hysterectomy, BSO: bilateral salpingo-oophorectomy, CHT: chemotherapy; RT, radiation therapy.
6 C. Abraham et al. / Gynecologic Oncology Reports 11 (2015) 4–6therapeutic approach for this disease entity. Further research is required
to potentially identify “targetable” driver mutations.
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